Real world outcomes of darolutamide efficacy and safety in treating non-metastatic and metastatic hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results